Fatty liver: What diseases this liver condition can trigger

Fat accumulation in the liver, common in both non-drinkers (NAFLD, now MASLD) and those who consume alcohol (AFLD), may initially feel harmless. Yet, it can quietly trigger a chain reaction of serious health conditions if it's not addressed early. Below, we explore how fatty liver can escalate into multiple diseases beyond the liver itself—and what makes early action so important.

Fatty liver can evolve into MASH (Metabolic Dysfunction–Associated Steatohepatitis), formerly known as NASH, when simple fat buildup leads to inflammation and liver-cell injury. That inflammation frequently causes scarring (fibrosis), which over time may progress into cirrhosis or even liver cancer.

​10 walking habits to avoid​

Although defined as a liver condition, fatty liver patients are far more likely to die from heart-related issues. NAFLD and MASH drive systemic inflammation, endothelial dysfunction, hypertension, and ectopic fat deposition in vessels and organs—all accelerating atherosclerosis. Cardiovascular disease is the most common cause of death in this population

In fact, patients with NAFLD face roughly a 1.5–2‑fold increased risk of heart attacks, strokes, and cardiovascular mortality—independent of typical risk markers

Fatty liver and insulin resistance are closely linked. Excess liver fat impairs glucose regulation, raising risk of type 2 diabetes. In return, diabetes worsens liver inflammation and steatosis. Evidence shows people with NAFLD have nearly double the risk of developing diabetes, and once diabetes sets in, liver disease accelerates rapidly

The same systemic changes that fuel fatty liver—chronic inflammation, endothelial damage, and insulin resistance—also harm kidney function. Studies show people with both NAFLD and diabetes who develop CKD face significantly higher rates of heart attacks, strokes, and mortality. Advanced liver fibrosis is independently tied to the risks of kidney dysfunction as well

Fatty liver often accompanies—and may contribute to—conditions like PCOS, hypothyroidism, and other metabolic endocrine imbalances. Women with PCOS frequently show insulin resistance and increased liver fat. Even people with normal weight can develop MASLD if metabolic dysfunction is present. Symptoms such as unexplained fatigue, mild abdominal pain, or skin changes may appear long before a liver test flags a problem

Fatty liver disease affects nearly 25–30% of adults in Europe and the U.S, with an increasing incidence among young people—even in their 20s. As many as five million Europeans and Americans may unknowingly live with MASH, and diagnosis rates are alarmingly low (<18%)

That matters because the liver’s ability to recover is highest before advanced fibrosis. Once scarring begins, recovery slows—and complications multiply. Without early intervention, global healthcare costs and burden are expected to surge over the next two decades.

Ask for evaluation if you have risk factors such as obesity, type 2 diabetes, hypertension, PCOS, or persistently elevated liver enzymes. Diagnostic options include blood tests, imaging, and in some cases a liver biopsy to confirm inflammation or scarring.

Seek help if you experience:

• Persistent fatigue or mental fog
• Upper-right abdominal discomfort
• Unexplained weight loss, swelling, or yellow skin/eyes

These symptoms may signal MASH progressing toward cirrhosis or its complications, and early intervention can make a huge difference